4. As of noon trading, Biogen Idec ( BIIB) is down $4.57 (-1.6%) to $275.76 on light volume. Thus far, 215,155 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $275.75-$280.84 after having opened the day at $279.80 as compared to the previous trading day's close of $280.33. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $66.0 billion and is part of the health care sector. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.